Skip to main content

Table 1 Demographic and selected baseline features, itemized by switch status. Categorical data are shown by N (%), metric data by µ ± SD. Percentages may not sum up to 100% in case of missing data

From: Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study

Parameter

Non-Switch (N = 714)

Missing data (N)

Switch (N = 153)

Missing data (N)

p-value

Demography

 Sex [Female]

640 (89.6%)

-

128 (83.7%)

-

0.0487

 Age [years]

45.0 ± 12.5

-

48.0 ± 11.7

-

0.0045

 Caucasian Race

672 (94.1%)

-

145 (94.8%)

-

0.8504

Height, Weight and BMI

 Height [cm]

168.7 ± 7.6

279

168.4 ± 8.2

85

0.7717

 Weight [kg]

71.9 ± 15.5

279

70.5 ± 15.6

85

0.4820

 BMI [kg/m2]

25.3 ± 5.0

279

24.8 ± 5.2

85

0.5490

Lifestyle

 Alcohol consumption

 

95

 

85

0.1459

 No Alcohol

273 (38.2%)

 

73 (47.7%)

  

 Irregular Alcohol

342 (47.9%)

 

63 (41.2%)

  

 Regular Alcohol

4 (0.6%)

 

0 (0.0%)

  

 Smoking status

 

87

 

13

0.5747

 Non-Smoker

497 (69.6%)

 

110 (71.9%)

  

 Former Smoker

54 (7.6%)

 

14 (9.2%)

  

 Smoker

76 (10.5%)

 

16 (10.5%)

  

Medical Historya

 None

176 (24.6%)

-

25 (16.3%)

-

0.0268

 Heart Diseases

78 (10.9%)

-

23 (15.0%)

-

0.1646

 Endocrine Diseases

115 (16.1%)

-

28 (18.3%)

-

0.5482

 Skeletal muscle, connective tissue and bone disorders

127 (17.8%)

-

34 (22.2%)

-

0.2083

 Other neurological conditions

97 (13.6%)

-

31 (20.3%)

-

0.0438

 Psychiatric diseases

282 (39.5%)

-

85 (55.6%)

-

0.0003

  1. aOnly SOCs reported for > 10% of total patients are shown